Program milestone guides
Step-by-step explainers place public funding, study development, federal review, and public announcements in sequence. The focus is what a milestone may signal—and what it does not establish about availability or safety.
Quiet Harbor 52 / Information services
Guides, comparisons, and research summaries for people following ibogaine research in Texas—organized to make the distinction between research activity, policy change, and routine treatment access easier to see.
A clearer starting point
Quiet Harbor 52 assembles plain-language materials for Texans, veterans, families, researchers, policymakers, and clinicians who want to follow an evolving pathway without confusing public interest or trial planning with routine care.
Use the Texas ibogaine research overview to orient around the subject first, then use the services below to compare milestones, terms, and open questions. For the purpose and standards behind this work, see how Quiet Harbor 52 approaches its material.
What we organize
Each offering is informational: it is designed to make research and policy developments more legible, not to assess an individual situation or recommend a course of treatment.
Step-by-step explainers place public funding, study development, federal review, and public announcements in sequence. The focus is what a milestone may signal—and what it does not establish about availability or safety.
Comparison notes separate research authorization from routine treatment access, helping readers keep different legal and practical questions apart as Texas discussions develop.
Research summaries identify what a study is examining, the limits of an early finding, and the safety context that belongs beside efficacy discussions. The National Institute on Drug Abuse’s ibogaine research overview likewise describes ongoing scientific interest while noting important safety concerns.
Short definitions and question sets make technical language more usable for non-specialists. This includes context for why a controlled-substance classification matters: the DEA’s scheduling explanation describes how federal schedules shape regulatory treatment of substances.
A practical reading order
The timeline materials are arranged to clarify the difference between a public proposal, a funded research effort, a trial milestone, and a change in ordinary access. That distinction matters because ibogaine has a complex history and remains a subject of regulation; its broader background is summarized in the Wikipedia entry on ibogaine.
“Research activity can be meaningful without becoming a promise of access, safety, or outcome.”
Common scope questions
The goal is to provide organized context for a complicated topic while keeping medical, legal, and regulatory limits visible.
No. Quiet Harbor 52 is an independent information resource. Its guides provide context on research, policy, terminology, and questions to consider; they are not medical or legal advice.
No. Research authorization and routine treatment access are different questions. A program timeline can help distinguish trial activity, funding, federal constraints, and public discussion from ordinary clinical availability.
The materials are for Texans, veterans, families, researchers, policymakers, and clinicians seeking careful context on ibogaine research developments. The stakeholder guide organizes some of the distinct questions different audiences may carry.
Continue with the record
For a milestone-by-milestone view of the Texas pathway, continue to the program timeline and use it alongside the explanatory guides on this site.